Analysis of the occurrence and liver function characteristics of arsenic-associated liver injury during the treatment of pediatric patients with acute promyelocytic leukemia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05954-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Yuxuan Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Epidemiology and Evidence-Based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children H…. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Chemical and Drug Induced Liver Injury, Arsenic Trioxide. Die Arbeit nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Liver injury during arsenic treatment for acute promyelocytic leukemia was previously reported in adults, but not comprehensively in children until now. This study aims to investigate liver injury in pediatric patients with APL, changes in liver function during treatment, and compare the effects of Arsenic trioxide (ATO) and Realgar-Indigo naturalis formula (RIF) on liver function. One hundred and eighty-six patients with 3076 patient tests were analyzed, who were enrolled in the Chinese Children's Leukemia Group (CCLG)-APL2016 Protocol database between November 2016 and November 2018 in 38 hospitals across China(ChiCTR-OIN-17011227). Twenty of 164 patients (12.2%) suffered from liver injury after treatment with arsenic. In addition, sixteen (80%) cases of liver injury occurred during the induction period of treatment. What's not disheartening was that 18 (90%) cases of liver injury were transient, occurring at a median time of 17 days after exposure to arsenic. More importantly, the risk of liver injury associated with RIF was not higher than that associated with ATO (RR = 0.854, 95% CI: 0.292-2.495). Otherwise, the ALP of 18 cases of liver injury was not higher than the ULN of ALP. Thus, the incidence of liver injury associated with arsenic in pediatric patients with APL was similar to that in adult patients and the risk of liver injury associated with RIF was not higher than that associated with ATO. Since ALP was not higher in pediatric APL patients with liver injury, further research is needed to explore whether ALP is an index of liver injury in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Epidemiology and Evidence-Based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children Health, No.56 Nanlishi Road, Beijing, 100045, China.
- Hematology Center, National Key Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Childr…
- Center for Clinical Epidemiology and Evidence-Based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children Health, No.56 Nanlishi Road, Beijing, 100045, China. pengxiaoxia@bch.co…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, Y., Wang, L., Peng, Y., Nie, X., Yan, R., & Peng, X. (2024). Analysis of the occurrence and liver function characteristics of arsenic-associated liver injury during the treatment of pediatric patients with acute promyelocytic leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-05954-y
Vancouver
Yang Y, Wang L, Peng Y, Nie X, Yan R, Peng X. Analysis of the occurrence and liver function characteristics of arsenic-associated liver injury during the treatment of pediatric patients with acute promyelocytic leukemia. Annals of Hematology. 2024. doi:10.1007/s00277-024-05954-y
BibTeX
@article{Yang2024,
author = {Yang, Yuxuan and Wang, Linya and Peng, Yaguang and Nie, Xiaolu and Yan, Ruohua and Peng, Xiaoxia},
title = {Analysis of the occurrence and liver function characteristics of arsenic-associated liver injury during the treatment of pediatric patients with acute promyelocytic leukemia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05954-y}
}
EUVIMED